(BDX) Becton Dickinson - Ratings and Ratios
Catheters, Syringes, Infusion, Diagnostics, Surgical
BDX EPS (Earnings per Share)
BDX Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 22.2% |
| Value at Risk 5%th | 34.3% |
| Relative Tail Risk | -6.11% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.52 |
| Alpha | -24.96 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.393 |
| Beta | 0.506 |
| Beta Downside | 0.678 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.06% |
| Mean DD | 15.59% |
| Median DD | 15.38% |
Description: BDX Becton Dickinson September 26, 2025
Becton, Dickinson and Company (NYSE: BDX) is a diversified medical-technology firm that designs, manufactures, and markets a broad portfolio of products ranging from basic medical supplies (e.g., syringes, needles) to sophisticated diagnostic and interventional devices. Its customers span hospitals, physician offices, clinical laboratories, pharmaceutical manufacturers, and end-users worldwide, positioning the company as a core supplier across the healthcare value chain.
The business is organized into three operating segments. The **BD Medical** segment focuses on vascular access and infusion therapy, offering peripheral and central catheters, needle-free connectors, drug-transfer devices, and pharmacy automation solutions. The **BD Life Sciences** segment supplies specimen collection tools, automated culture and molecular testing platforms, flow cytometry instruments, and reagents for genomics and oncology applications. The **BD Interventional** segment delivers surgical and critical-care products, including hernia repair meshes, bio-resorbable grafts, infection-prevention solutions, and peripheral-intervention devices. These segments together generate roughly 55 % (Medical), 30 % (Life Sciences), and 15 % (Interventional) of total revenue, based on the latest segment reporting.
**Key performance indicators** (as of FY 2024) include: total revenue of $25.4 billion, a 6 % year-over-year increase driven primarily by strong demand for automated pharmacy systems and molecular diagnostics; an operating margin of 13.8 %, reflecting ongoing cost-discipline and scale efficiencies; and free cash flow of $2.9 billion, supporting a dividend yield of ~1.5 % and a share-repurchase program. **Sector drivers** such as an aging global population, rising hospital inpatient volumes, and accelerated adoption of point-of-care testing are expected to sustain demand for BDX’s product mix. Conversely, **macroeconomic uncertainties**-including potential supply-chain disruptions and fluctuating foreign-exchange rates-could pressure margins, especially in the capital-intensive Life Sciences segment.
For a deeper quantitative assessment of BDX’s valuation relative to peers, the ValueRay platform offers a granular, data-driven dashboard worth exploring.
BDX Stock Overview
| Market Cap in USD | 50,974m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1987-01-01 |
| Return 12m vs S&P 500 | -25.2% |
| Analyst Rating | 3.59 of 5 |
BDX Dividends
| Dividend Yield | 2.15% |
| Yield on Cost 5y | 1.90% |
| Yield CAGR 5y | 5.65% |
| Payout Consistency | 81.2% |
| Payout Ratio | 28.9% |
BDX Growth Ratios
| CAGR 3y | -2.62% |
| CAGR/Max DD Calmar Ratio | -0.07 |
| CAGR/Mean DD Pain Ratio | -0.17 |
| Current Volume | 3976.4k |
| Average Volume | 2692.2k |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.52b TTM) > 0 and > 6% of Revenue (6% = 1.31b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -1.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.33% (prev 28.25%; Δ -23.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 3.25b > Net Income 1.52b (YES >=105%, WARN >=100%) |
| Net Debt (18.33b) to EBITDA (4.62b) ratio: 3.96 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (287.1m) change vs 12m ago -1.08% (target <= -2.0% for YES) |
| Gross Margin 45.05% (prev 42.06%; Δ 2.99pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 39.25% (prev 35.67%; Δ 3.58pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.79 (EBITDA TTM 4.62b / Interest Expense TTM 616.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.89
| (A) 0.02 = (Total Current Assets 9.26b - Total Current Liabilities 8.31b) / Total Assets 55.33b |
| (B) 0.30 = Retained Earnings (Balance) 16.43b / Total Assets 55.33b |
| (C) 0.04 = EBIT TTM 2.34b / Avg Total Assets 55.45b |
| (D) 0.50 = Book Value of Equity 14.98b / Total Liabilities 29.94b |
| Total Rating: 1.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.36
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.68% = 1.84 |
| 3. FCF Margin 11.71% = 2.93 |
| 4. Debt/Equity 0.76 = 2.22 |
| 5. Debt/Ebitda 3.96 = -2.50 |
| 6. ROIC - WACC (= -0.31)% = -0.39 |
| 7. RoE 6.00% = 0.50 |
| 8. Rev. Trend 84.86% = 6.36 |
| 9. EPS Trend 77.73% = 3.89 |
What is the price of BDX shares?
Over the past week, the price has changed by +8.82%, over one month by +3.42%, over three months by -0.95% and over the past year by -14.77%.
Is Becton Dickinson a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BDX is around 177.95 USD . This means that BDX is currently overvalued and has a potential downside of -7.82%.
Is BDX a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 201.5 | 4.4% |
| Analysts Target Price | 201.5 | 4.4% |
| ValueRay Target Price | 192.8 | -0.1% |
BDX Fundamental Data Overview November 11, 2025
P/E Trailing = 32.4526
P/E Forward = 12.8205
P/S = 2.334
P/B = 2.1559
P/EG = 0.9859
Beta = 0.285
Revenue TTM = 21.77b USD
EBIT TTM = 2.34b USD
EBITDA TTM = 4.62b USD
Long Term Debt = 17.53b USD (from longTermDebt, last quarter)
Short Term Debt = 1.56b USD (from shortTermDebt, last quarter)
Debt = 19.18b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 18.33b USD (from netDebt column, last quarter)
Enterprise Value = 69.30b USD (50.97b + Debt 19.18b - CCE 859.0m)
Interest Coverage Ratio = 3.79 (Ebit TTM 2.34b / Interest Expense TTM 616.0m)
FCF Yield = 3.68% (FCF TTM 2.55b / Enterprise Value 69.30b)
FCF Margin = 11.71% (FCF TTM 2.55b / Revenue TTM 21.77b)
Net Margin = 7.01% (Net Income TTM 1.52b / Revenue TTM 21.77b)
Gross Margin = 45.05% ((Revenue TTM 21.77b - Cost of Revenue TTM 11.96b) / Revenue TTM)
Gross Margin QoQ = 47.50% (prev 42.81%)
Tobins Q-Ratio = 1.25 (Enterprise Value 69.30b / Total Assets 55.33b)
Interest Expense / Debt = 0.81% (Interest Expense 155.0m / Debt 19.18b)
Taxrate = 3.33% (17.0m / 510.0m)
NOPAT = 2.26b (EBIT 2.34b * (1 - 3.33%))
Current Ratio = 1.11 (Total Current Assets 9.26b / Total Current Liabilities 8.31b)
Debt / Equity = 0.76 (Debt 19.18b / totalStockholderEquity, last quarter 25.39b)
Debt / EBITDA = 3.96 (Net Debt 18.33b / EBITDA 4.62b)
Debt / FCF = 7.19 (Net Debt 18.33b / FCF TTM 2.55b)
Total Stockholder Equity = 25.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.76% (Net Income 1.52b / Total Assets 55.33b)
RoE = 6.00% (Net Income TTM 1.52b / Total Stockholder Equity 25.43b)
RoCE = 5.44% (EBIT 2.34b / Capital Employed (Equity 25.43b + L.T.Debt 17.53b))
RoIC = 5.04% (NOPAT 2.26b / Invested Capital 44.82b)
WACC = 5.35% (E(50.97b)/V(70.15b) * Re(7.07%) + D(19.18b)/V(70.15b) * Rd(0.81%) * (1-Tc(0.03)))
Discount Rate = 7.07% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.76%
[DCF Debug] Terminal Value 79.85% ; FCFE base≈2.82b ; Y1≈3.16b ; Y5≈4.20b
Fair Price DCF = 253.9 (DCF Value 72.77b / Shares Outstanding 286.6m; 5y FCF grow 13.83% → 3.0% )
EPS Correlation: 77.73 | EPS CAGR: 10.89% | SUE: 0.27 | # QB: 0
Revenue Correlation: 84.86 | Revenue CAGR: 10.53% | SUE: -0.05 | # QB: 0
Additional Sources for BDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle